William Blair analyst Matt Phipps has maintained their bullish stance on INKT stock, giving a Buy rating today.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Matt Phipps has given his Buy rating due to a combination of factors surrounding MiNK Therapeutics’ recent developments and future potential. The company has reported promising first-quarter financial results and is on track to present a clinical update on its Phase II study of agenT-797 in gastric cancer, which is being conducted by Memorial Sloan Kettering. This study is significant as it involves advanced treatments for patients with GE adenocarcinoma who have undergone at least one prior line of therapy.
Additionally, MiNK Therapeutics has disclosed a noteworthy outcome from its Phase I trial, where a patient with metastatic testicular cancer achieved complete remission after a single infusion of agenT-797. This result highlights the potential efficacy of their treatment approach, and a detailed publication on this case is anticipated in the first half of 2025. These factors collectively contribute to the positive outlook and Buy rating given by Matt Phipps.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $35.00 price target.